Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared ITI’s Investigational New Drug (IND) application for ITI-5000. This clearance allows ITI to initiate the first-in-human clinical trial evaluating ITI-5000, a UNITE®-based self-amplifying RNA vaccine, as monotherapy and in combination with pembrolizumab (Keytruda®), in patients with Sta

The European Commission approved Bayer's higher-dose version of Eylea (aflibercept) for the treatment of patients with visual impairment due to macular oedema following retinal vein occlusion (RVO) including branch, central and hemiretinal vein occlusion. The clearance, announced Friday, marks the third indication for the 8-mg formulation of the VEGF inhibitor. The EU approval "expands the range of retinal indications for Eylea 8 mg – now encompassing wet age-related macular degeneration, diabe

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps Jan. 16, 2026 -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Jan. 20, 2026 -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical tri

Jan. 20, 2026 -- Think Bioscience ("Think Bio"), a biotechnology company focused on unlocking elusive drug targets, has raised $55M in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Think Bioscience develops small molecule drugs for historically challenging

The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell Engager (BRiTE), yields precise and potent anti-tumor activity by redirecting T cells to bind and destroy cancer cells in the brain Dose-response efficacy and favorable safety profile observed by Duke University scientists in preclinical studies Jan. 20, 2026 -- Adaptin Bio, Inc. (“Adaptin” or the “Com

Jan. 20, 2026 -- Tanabe Pharma America, Inc., the wholly owned subsidiary of Tanabe Pharma Corporation, today announced positive topline efficacy and safety results from the global Phase 3 clinical trial, also known as the INSPIRE study, of investigational dersimelagon (MT-7117), a selective melanocortin-1 receptor (MC1R) agonist, being developed for the oral treatment of adult and adolescent patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). EPP and XLP are ra

Jan. 16, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were appr

Jan. 16, 2026 -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the commercial availability of the Freedom® PNS System for the treatment of chronic craniofacial pain. Freedom PNS is now the first and only PNS System in the United States available for this indication and supported by data from an FDA-approved Investigational Device Exemption (IDE) clinical study, allowing a greater patient population to benefit from PNS therapy. Craniofaci

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population Jan. 15, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range